The 30th Indonesian Neuroimmunology Case Teleconference
Program |
Mailing List |
Connection Information |
Files |
Report |
ver 2.1
The 30th Indonesian Neuroimmunology Case Teleconference
* For more information, please refer to the TEMDEC policy.
The 30th Indonesian Neuroimmunology Case Teleconference
| Local Time at Main Venue | 2021.10.15(Fri) 13:00 - 90min, Jakarta, ID (UTC+07:00) |
| Organizer | Riwanti Estiasari |
| Topic | NPSLE case manifesting as polyneuropathy and GBS and Acute Visual Loss after Covid-19 Vaccination |
| Contents | Neurology |
| Style | Conference |
| Connection Method | H.323, Zoom |
| Server At | Kyushu University |
| Access Information | |
| Brief Description | Case 1. A 38-year-old man who was admitted to the hospital because of acute visual loss. He complained with sudden and severe acute visual loss for three days before admission. He did not have any history of a visual loss before. He had history of Covid-19 vaccination, and 12 hours after the injection, he starts complained of blurred vision. Case 2. A case of a 39 years old female coming to us with progressive weakness in all extremities since 2 weeks ago. Weakness was followed by socks and gloves hypoesthesia in all extremities. Fever occurred prior to weakness. There was history of covid-19 infection 6 months before. Similar episode of complaints occurred 8 months before and treated as SGB which recovered fully with IVIg administration. |
Key Members
| Chair | Riwanti Estiasari | University of Indonesia | ID |
| Co-Chair 1 | Takuya Matsushita | Kochi University | JP |
| Co-Chair 2 | - | - | - |
| Chief Engineer 1 | Nopa Krismanto | University of Indonesia | ID |
| Chief Engineer 2 | - | - | - |
| Chief Engineer 3 | - | - | - |
| Chief Engineer 4 | - | - | - |
Connecting Institutions
Red is to be decided| City, Country | Institution | Moderator | Local Engineer | |
|---|---|---|---|---|
| 1(Main). | Jakarta, ID | University of Indonesia | Riwanti Estiasari | Nopa Krismanto |
| 2. | Manado, ID | Sam Ratulangi University | Arthur Mawuntu | - |
| 3. | Yogyakarta, ID | Gadjah Mada University | Cempaka Thursina | Yanuarten Trianto Budiman |
| 4. | Malang, ID | Brawijaya University | Badrul Munir | Kuswindarto |
| 5. | Palembang, ID | Sriwijaya University | Andika okparasta | Dwi basuki |
| 6. | Jawa Timur, ID | Airlangga University | Devi Ariani | Agus adianto |
| 7. | Fukuoka, JP | Kyushu University Hospital | Takuya Matsushita | Shunta Tomimatsu |
Schedule
| Main venue | Localtime | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.Jakarta, ID (UTC+07:00) | Contents | Presenter | UTC+08:00 (Institution No. 2) | UTC+07:00 (Institution No. 3, 4, 5, 6) | UTC+09:00 (Institution No. 7) | |||||||||||||||||
| 2021.10.15 12:30 - 13:00 | Connection starts & last preparations | 2021.10.15 13:30 - 14:00 | 2021.10.15 12:30 - 13:00 | 2021.10.15 14:30 - 15:00 | ||||||||||||||||||
| 13:00 - 13:03 | Opening remarks and self-introduction | All center | 14:00 - 14:03 | 13:00 - 13:03 | 15:00 - 15:03 | |||||||||||||||||
| 13:03 - 13:23 | Acute Visual Loss after Covid-19 Vaccination | Fahima, MD(Brawijaya University) | 14:03 - 14:23 | 13:03 - 13:23 | 15:03 - 15:23 | |||||||||||||||||
| 13:23 - 14:00 | Case 1 discussion | All center | 14:23 - 15:00 | 13:23 - 14:00 | 15:23 - 16:00 | |||||||||||||||||
| 14:00 - 14:10 | NPSLE case manifesting as polyneuropathy and GBS | Ashita Hulwah, MD(Sriwijaya University) | 15:00 - 15:10 | 14:00 - 14:10 | 16:00 - 16:10 | |||||||||||||||||
| 14:10 - 14:25 | Case 2 discussion | All center | 15:10 - 15:25 | 14:10 - 14:25 | 16:10 - 16:25 | |||||||||||||||||
| 14:25 - 14:30 | Closing | All center | 15:25 - 15:30 | 14:25 - 14:30 | 16:25 - 16:30 | |||||||||||||||||
Precautions
- The conference will be recorded by the photos and movies.
- Pictures taken at the conference will be published in TEMDEC home page, annual report and conference presentations.
- Do not present the personal information of patients any in oral and presentation materials without obtaining the patient's consent.
* For more information, please refer to the TEMDEC policy.